Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 2Lymphoid 2Myeloid 1

Conditions

Lymphoma 4Lymphoma, Non-Hodgkin 3Leukemia 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Hodgkin Disease 1Cardiotoxicity 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 346Cytarabine 282fludarabine phosphate 203Methotrexate 186Filgrastim 159Busulfan 148Etoposide 135Peripheral Blood Stem Cell Transplantation 134fludarabine 128Rituximab 119Radiotherapy 111Vincristine 102Cyclosporine 98Daunorubicin 96Antilymphocyte Serum 94Dexamethasone 91Tacrolimus 86Mycophenolic Acid 86Whole-Body Irradiation 81Melphalan 79Imatinib Mesylate 69Idarubicin 67Mercaptopurine 66Granulocyte Colony-Stimulating Factor 66Azacitidine 65Methylprednisolone 59Prednisone 58Doxorubicin 58Clofarabine 54sargramostim 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia × Electrocardiography × Other hematologic neoplasm × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡